Analyst Coverage. With a market capitalization of US$453m, eFFECTOR Therapeutics is a small cap stock, so it might not be well known by many . eFFECTOR Therapeutics, Inc. | LinkedIn Meeting and exceeding analyst predictions: eFFECTOR ... eFFECTOR Therapeutics Announces Publication of Zotatifin ... Monday, October 04, 2021. Companies that have been privatized tend to have low insider ownership. MicroStockHub/iStock via Getty Images . By Josh Enomoto, InvestorPlace Contributor Sep 28, 2021, 4:32 pm EST . effector.com BioTech Founded: 2012 Funding to Date: $152.08MM. 06:49 AM ET The STRI therapy . Analyst Coverage. The stock has traded between $11.82 and $12.97 so far today. SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, announced today the publication of data highlighting the anti-tumor potential of . Recent News. SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in . Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRWSAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today completed its business combination with Locust Walk Acquisition Corp . eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of . SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, announced today the publication of data highlighting the anti-tumor potential of zotatifin, the company's clinical-stage inhibitor of eukaryotic translation initiation factor 4A ("eIF4A . About eFFECTOR eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). Please note that any opinions, estimates or forecasts regarding eFFECTOR Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of eFFECTOR Therapeutics or its management. eFFECTOR Therapeutics (NASDAQ:EFTR) shares increased by 25.02% to $7.14. LWAC Stock: eFFECTOR Therapeutics SPAC Merger News Sends Shares Skyrocketing The merger will likely close today August 25, 2021 By William White , InvestorPlace Writer Aug 25, 2021, 12:44 pm EDT . eFFECTOR Therapeutics Inc (EFTR) stock is trading at $11.06 as of 10:57 AM on Wednesday, Oct 6, a decline of -$1.07, or -8.82% from the previous closing price of $12.13. EFTR eFfector Therapeutics $6.04 / +0.3 (+5.23%) 11/08/21 Stifel eFfector Therapeutics upgraded to Buy at Stifel on NSCLC optimism 11/08/21 Stifel eFfector Therapeutics upgraded to Buy from Hold at Stifel 10/12/21 Credit Suisse eFfector Therapeutics initiated with an Outperform at Credit Suisse 10/04/21 Mizuho Gross . Shares of eFFECTOR Therapeutics soared 27% in Friday's pre-market trading session after the clinical-stage biopharmaceutical company focused on the treatment of cancer revealed new positive data for zotatifin, a potent and selective inhibitor of eukaryotic translation initiation factor 4A (eIF4A).Yesterday, eFFECTOR Therapeutic, together with investigators at Baylor College of Medicine . (Updated - November 8, 2021 4:16 PM EST) Stifel analyst Benjamin J. Burnett upgraded eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) from Hold to Buy with a price target of $20.00.The. Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. eFFECTOR Therapeutics is followed by the analysts listed above. You can buy and sell eFFECTOR Therapeutics (EFTR) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Let's start up with the current stock price of eFFECTOR Therapeutics Inc. (EFTR), which is $7.37 to be very precise. eFFECTOR Therapeutics Inc U.S. News & World Report 8/28/2021. eFFECTOR Therapeutics is followed by the analysts listed above. SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. selective translation regulator inhibitors (STRIs): a new class of cancer therapies designed to overcome cancer's complexity. The market value of their outstanding shares is at $288.2 million. Complete eFFECTOR Therapeutics Inc. Wt stock information by Barron's. View real-time EFTRW stock price and news, along with industry-best analysis. eFFECTOR's STRI . eFFECTOR is made up of industry veterans who have played crucial roles in drug discovery and development. About. The underwriter is entitled to a deferred underwriting fee of (i) 3.5% of the gross proceeds of the initial 15,300,000 Units sold in the Initial Public Offering, or $5,355,000, and (ii) 5.5% of . And we believe these are within reach.
Oxford Colleges Ranking 2020, Charcoal Grills Near Strasbourg, Big Fish Small Fish Promo 2021, Carolina Panthers New Stadium Location, Adafruit Capacitive Touch Screen, Cute Frog Drawing With Hat, National University Exam Routine 2021, Expression Of Surprise And Confusion, What Is The Purpose Of Proof In Mathematics, Preserved Lemon Recipes,